Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Department of Veterans Affairs |
---|---|
Information provided by: | Department of Veterans Affairs |
ClinicalTrials.gov Identifier: | NCT00323271 |
The purpose of this study is to evaluate the efficacy of a brief psychological intervention, cognitive-behavior therapy, for the management of persistent pain associated with Multiple Sclerosis.
Condition | Intervention |
---|---|
Multiple Sclerosis |
Behavioral: Cognitive-behavior therapy Other: Interventional |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Cognitive-Behavior Therapy for MS-Related Chronic Pain |
Estimated Enrollment: | 124 |
Study Start Date: | July 2006 |
Estimated Study Completion Date: | March 2010 |
Estimated Primary Completion Date: | March 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Behavioral
|
Behavioral: Cognitive-behavior therapy
CBT: The components of CBT include (1) identification of idiosyncratic beliefs about pain and pain treatment, as well as reconceptualization of the pain experience as subject to personal control (sessions 1-2), (2) instruction in specific cognitive (e.g., distraction) and behavioral (e.g., change in activity patterns such as alternating activity with periods of rest) skills (sessions 3-8), and (3) consolidation of cognitive/behavioral skills through activities such as role playing (sessions 9-11).
|
2: Active Comparator
Educational
|
Other: Interventional
Educational intervention: Session topics will include information on the etiology of MS, MS subtypes and disease progression, common symptoms of MS, medical management of MS, rehabilitation approaches to management of MS-related symptoms, exercise, sick day management, stress management, psychosocial adjustment, family involvement, and appropriate use of the health care system.
|
The primary purpose of the proposed study is to evaluate the feasibility and efficacy of tailored CBT with standard pharmaceutical care (CBT/SC) in reducing pain, disability, and distress among persons with Multiple Sclerosis (MS) related pain conditions. This will entail: (1) evaluating the feasibility, perceived credibility, participation and adherence rates, and satisfaction related to CBT, (2) conducting a randomized controlled trial of the efficacy of CBT relative to an education control/standard care (ED/SC) condition, and (3) evaluating possible predictors of treatment response including demographics, disease-relevant variables, cognitive functioning, and motivation or readiness to adopt a self-management approach to MS-related pain.
Research Design: A randomized mixed factorial controlled design will be employed in which CBT/SC is compared to EDSC. Repeated assessments of key outcome domains will occur at pretreatment/baseline, at 15 weeks (post-treatment), and 20, 36, and 52 (follow-up) weeks.
Methodology: Participants in this trial will be 124 persons with MS (including veterans and non-veterans) who report persistent MS-related pain (e.g., neuropathic pain, pain related to muscle spasms, neuralgias) of at least moderate intensity (pain severity of 4 or greater on the numeric rating scale) despite optimal pharmacological management. Participants must be at least 21 years of age and able to provide informed consent. Exclusion criteria include: (1) pending surgery or interventional anesthesiological procedures for pain, (2) currently psychotic or actively suicidal or homicidal, (3) current alcohol or substance abuse or dependence, (4) presence of other life threatening illnesses, (5) the presence of profound cognitive impairment rendering successful participation in CBT or ED impossible, (6) the presence of physical disabilities resulting in an inability to attend treatment sessions and/or inability to participate in telephone interventions (e.g., severe dysarthria), (7) prior or current psychological treatment for chronic pain, (8) two or more documented exacerbations of MS-related symptoms during the past year, and (9) current exacerbation of symptoms defined as sudden onset of symptoms within a 24 hour period. CBT will involve an innovative treatment approach that combines specific training in relevant cognitive and behavior skills targeting management of pain and the negative impacts of pain. The application of these skills for the management of coincident symptoms of MS (e.g., spasticity, fatigue, abnormal sensory experiences) will also be encouraged. ED will involve provision of a broad array of educational material regarding MS and its management, but it will not explicitly inform participants about non-pharmacological strategies for management of pain. Both treatments will involve seven 60 minute, outpatient individual treatment sessions offered every other week, interspersed with five, 30 minute individual telephone sessions (one final face-to-face session will be 30 minute individual telephone sessions will be included) provided by a psychologist and supported by patient education and treatment guides that have been developed for the study. Participants will be randomly assigned to one of two treatment arms: CBT/SC or ED/SC. Recruitment rates, session adherence, dropout rates, and participants' ratings of comprehension, treatment credibility, treatment satisfaction and adherence to therapist recommendations will be used to assess feasibility of the treatment and recruitment methods. Multiple standardized measures of each outcome domain of interest will be obtained, including pain severity, disability, affective distress, and quality if life. The analysis of each of the primary and secondary outcome measures (summary measures of pain intensity, pain-related disability, MS-related disability, and emotional functioning) will be by a repeated measures mixed effects model27. The outcome variable in each model will be the changes at each follow-up visit relative to baseline, with the baseline value included as a covariate in the model. Several possible predictors of treatment adherence and outcome will be examined, including participant demographics (e.g., age, gender, ethnicity), disease-relevant variables (e.g.., MS subtype, disease duration, disease severity, level of cognitive functioning), outcome measures (e.g., pain severity, depressive symptom severity), and a measure of motivation for adoption of a self-management approach to chronic pain.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Patricia H Rosenberger | (203) 932-5711 ext 2674 | patricia.rosenberger@va.gov |
United States, Connecticut | |
VA Connecticut Health Care System (West Haven) | Recruiting |
West Haven, Connecticut, United States, 06516 | |
Contact: Patricia H Rosenberger 203-932-5711 ext 2674 patricia.rosenberger@va.gov | |
Contact: Robert D Kerns, PhD (203) 937-3841 robert.kerns@va.gov | |
Principal Investigator: Robert D. Kerns, PhD | |
United States, Massachusetts | |
VA Medical Center, Jamaica Plain Campus | Recruiting |
Boston, Massachusetts, United States, 02130 | |
Contact: James Kaufman, MD 857-364-5613 |
Principal Investigator: | Robert D. Kerns, PhD | VA Connecticut Health Care System (West Haven) |
Responsible Party: | Department of Veterans Affairs ( Kerns, Robert - Principal Investigator ) |
Study ID Numbers: | D4150R |
Study First Received: | May 5, 2006 |
Last Updated: | January 8, 2009 |
ClinicalTrials.gov Identifier: | NCT00323271 |
Health Authority: | United States: Federal Government |
Chronic pain Cognitive behavioral therapy Multiple sclerosis Randomized controlled trial |
Autoimmune Diseases Multiple Sclerosis Demyelinating Diseases Demyelinating Autoimmune Diseases, CNS |
Demyelinating diseases Sclerosis Pain Autoimmune Diseases of the Nervous System |
Pathologic Processes Immune System Diseases Nervous System Diseases |